AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01577979 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Message Reminder/Recall
Description: Adolescents will be randomly selected from the participating private practices and safety net organization clinics. Parents of selected adolescents will receive a text message to alert them that their child is due for a vaccine or well-care visit. The text message will provide response instructions. The responses can be one of three options: 1) the parent will call the clinic to schedule a visit, 2) the parent would like the clinic to call them to schedule a visit, or 3) the parent would like to stop any future text message reminders. Parents who would like the clinic to call them to schedule an appointment will be contacted by their child's provider to set up a visit. Parents may receive up to 3 text message reminders, unless they chose to stop any future messages.
Study NCT01577979 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Preference
Description: Parents of adolescents being seen within the managed care organization's intervention clinics will be asked about their reminder method preference at their child's 1st HPV immunization. The preference options include phone call, text message, or email. The preference for contact method will be recorded and utilized for the 2nd and 3rd dose reminders. The clinics' usual method of reminder will be used for all other parents.
Study NCT01028014 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pseudoephedrine
Description: Pseudoephedrine ER 120 mg by mouth once daily for 2 weeks
Study NCT01028014 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosin
Description: Tamsulosin 0.4mg by mouth daily for 2 weeks
Study NCT01028014 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imipramine
Description: Imipramine 25mg daily by mouth for 2 weeks
Study NCT04014608 — intervention group
Intervention type: OTHER
Intervention: Standard Practice to Prevent Hospital Onset CDI
Description: Bleach cleaning of rooms, use of required soap/water hand hygiene for CDI patients, hand hygiene monitoring, portable ultraviolet (UV) light room disinfection, and monitoring of room cleaning.
Study NCT01003899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: afatinib (BIBW 2992)
Description: afatinib (BIBW 2992) po QD
Study NCT00781209 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Irradiation plus Stereotactic Radiosurgery
Description: Posterior Fossa Irradiation-total dose of 37.5 Gy in 2.5 Gy fractions administered via conformal beams.~Radiosurgical boost-total dose administered to each lesion will be titrated to the size of the metastatic focus as follows:~Maximum Tumor Diameter:\<2.0 cm; Assigned Dose:24 Gy. Maximum Tumor Diameter:2.1-3.0 cm;Assigned Dose:18 Gy. Maximum Tumor Diameter:3.1-4.0 cm;Assigned Dose:15 Gy.
Study NCT01045629 — intervention group
Intervention type: OTHER
Intervention: Consent form education
Description: Randomly stratified schizophrenic patients group, some receive consent form education, the others not.
Study NCT00963365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6765
Description: Single oral dose and single IV infusion of AZD6765
Study NCT00963365 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AZD6765
Description: Single oral dose and single IV infusion of AZD6765
Study NCT00963365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6765
Description: Once-daily oral dose of AZD6765 or placebo on Day 1 and on Days 4 through 9.
Study NCT00963365 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AZD6765
Description: Once-daily oral dose of AZD6765 or placebo on Day 1 and on Days 4 through 9.
Study NCT02469493 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: acupuncture (Huatuo)
Description: The needles used were Huatuo brand (Suzhou, China) sterile disposable stainless steel filiform; needles sized 0.25\*25 mm. After disinfection, needles were inserted 0.5 to 0.8 inches into the skin and were manipulated manually to obtain Deqi. An electric stimulator (Huatuo SDZ-V, Suzhou, China) was connected to the needles and delivered a constant-current, 0.2-ms, density-wave, stimulus of 2 to 10-Hz frequency, level of intensity was as much as tolerable, but not painful to the subjects. The needles were left for 30 minutes and then removed.
Study NCT01640522 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Collaborative Care
Description: Collaborative care intervention to manage cancer-related symptoms
Study NCT01640522 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced usual Care
Study NCT00739648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP-376
Description: MP-376 administered via inhalation for 5 consecutive days within 28-day treatment cycles for up to 12 cycles
Study NCT00739648 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: same frequency as study drug using the same method of delivery
Study NCT04623931 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04623931 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT01028014 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclobenzaprine
Description: Cyclobenzaprine 10mg daily by mouth for 2 weeks
Study NCT01028014 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lactose capsule
Description: Lactose capsule 1 by mouth daily for 2 weeks
Study NCT01028014 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Solifenacin
Description: Solifenacin 5mg by mouth daily for 2 weeks
Study NCT00640913 — intervention group
Intervention type: PROCEDURE
Intervention: Reversal of defunctioning stoma
Description: Reversal of defunctioning stoma
Study NCT03465059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: A single oral dose of 80 mg Zanubrutinib will be administered.
Study NCT04623931 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study NCT04623931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO
Study NCT01815749 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells
Description: Given IV
Study NCT01815749 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous hematopoietic stem cell transplantation
Description: Undergo autologous hematopoietic stem cell transplantation
Study NCT01815749 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02068573 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ventilation
Description: The ventilation system is placed outside the house and provides filtered conditioned air to the child's bedroom, through insulated pipes mounted in a window opening. The window opening was built specifically for this purpose in form of a thermo plate replacing the window glass. The unit provides the bedroom with at least 2-3 air changes per hour
Study NCT02068573 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Ventilation
Description: The placebo unit (DUPLEX 370) is a completely similar installation to the active ventilation unit, but it only recirculates the air in the room instead of replacing it with fresh conditioned air.
Study NCT04280445 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychological therapy
Description: Acceptance and Commitment Therapy (ACT) is a trans-diagnostic approach which aims to promote better living by supporting clients through six key processes (e.g. mindfulness, values). ACT does not aim to reduce distress, rather its goal is to promote better living or a better quality of life despite distress (Hayes, Strosahl \& Wilson, 1999). ACT has been shown to have equal or superior efficacy to CBT with a number of psychological and physical health conditions (A-Tjak et al., 2015; Ruiz, 2012).
Study NCT01889953 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: EUS-guided biliary drainage
Description: Based on the patient's condition, the will receive:~* Rendezvous technique~* Direct transluminal access transesophageal technique~* Direct transluminal access transduodenal technique~* or direct transluminal access using transgastric approach
Study NCT02716974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide Acetate
Description: 22.5mg by intramuscular (IM) injection every 3 months
Study NCT02716974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Description: bicalutamide (Casodex) 50mg by mouth daily
Study NCT02716974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel (taxotere) 75 mg/m2 IV will be given on day 1 every 3 weeks, up to 6 cycles.
Study NCT05623540 — intervention group
Intervention type: DRUG
Intervention: Bisphosphonates, Combinations
Study NCT02716974 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prostatectomy
Description: Removal of the entire prostate gland, plus some surrounding tissue.
Study NCT02716974 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: 5 high dose radiation treatments to the metastatic (tumor has spread to other parts of the body) sites.
Study NCT03603665 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NTM-1633
Description: NTM-1633 is an equimolar mixture of three IgG1 monoclonal antibodies (mAb), referred to as XE02, XE06, and XE17 which bind to non-overlapping epitopes on Botulinum Neurotoxin (BoNT/E). Administered as a single intravenous infusion of NTM-1633 over one hour.
Study NCT03603665 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% Sodium Chloride Injection administered as a single intravenous infusion over one hour.
Study NCT01786512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omecamtiv Mecarbil Matrix F1 Formulation
Description: Modified release tablets for oral administration
Study NCT01786512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omecamtiv Mecarbil Matrix F2 Formulation
Description: Modified release tablets for oral administration
Study NCT01786512 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Modified release tablets matching to omecamtiv mecarbil
Study NCT01786512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omecamtiv Mecarbil Swellable Core Technology F2
Description: Modified release tablets for oral administration
Study NCT03735329 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diagnostic test of SPO2
Description: The SpO2 accuracy of the test devices will be evaluated over the oxygen saturation range between 70-100%.
Study NCT02469493 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: acupuncture (Huatuo)
Description: The needles used were Huatuo brand (Suzhou, China) sterile disposable stainless steel filiform; needles sized 0.25\*25 mm. After disinfection, needles were inserted 0.5 to 0.8 inches into the skin and were manipulated manually to obtain Deqi. An electric stimulator (Huatuo SDZ-V, Suzhou, China) was connected to the needles and delivered a constant-current, 0.2-ms, density-wave, stimulus of 2 to 10-Hz frequency, level of intensity was as much as tolerable, but not painful to the subjects. The needles were left for 30 minutes and then removed.
Study NCT02898350 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pulsed dye laser treatment
Description: Scar minimization with Pulsed dye laser treatment on suture removal day
Study NCT02898350 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CO2 laser treatment
Description: Scar minimization with CO2 laser treatment on suture removal day
Study NCT02898350 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Combined PDL and CO2 laser treatment
Description: Scar minimization with Pulsed dye laser and CO2 laser treatment on suture removal day
Study NCT02898350 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Split PDL and CO2 Laser treatment
Description: Split-scar with CO2 treatment after surgery and combined PDL and CO2 treatment on suture removal day
Study NCT03149887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Description: Liposomal bupivacaine solution (Exparel) for injection
Study NCT02764281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDA
Description: Methotrexate, 3.0g/m2/d iv, day 1~Etoposide, 100mg/m2 iv, day 2 to day 4~Dexamethasone, 40mg/d iv, day 1 to day 4~Pegaspargase, 2500IU/m2/d im, day 4~The MEDA chemotherapy will be repeated every 3 weeks.
Study NCT02764281 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Auto-HSCT
Description: Auto-HSCT will be performed with patients who responded to the initial MEDA chemotherapy with standard BEAM conditioning regimen.
Study NCT02165280 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Guided IMagery (GIM)
Description: It's a program of directed thoughts and suggestions that guide your imagination to a relaxed and focused state.
Study NCT01616238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Treatment for all pathways consists of Induction, Intensification (where applicable), Consolidation and Maintenance therapy during which combination chemotherapy is given for up to 2.5 years.
Study NCT02068508 — intervention group
Intervention type: DRUG
Intervention: Pioglitazone
Description: Pioglitazone Tablets
Study NCT02406027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54861911, 10 mg
Description: Participants will self-administer JNJ-54861911 tablet, 10 mg (2\*5 mg), orally, once daily.
Study NCT02406027 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: JNJ-54861911, 10 mg
Description: Participants will self-administer JNJ-54861911 tablet, 10 mg (2\*5 mg), orally, once daily.
Study NCT02406027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54861911, 25 mg
Description: Participants will self-administer 1 tablet of JNJ-54861911, containing 25 mg orally, once daily.
Study NCT02406027 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: JNJ-54861911, 25 mg
Description: Participants will self-administer 1 tablet of JNJ-54861911, containing 25 mg orally, once daily.
Study NCT02406027 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will self administer placebo matching to JNJ-54861911 orally once daily.
Study NCT02406027 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: JNJ-54861911, 5 mg
Description: Participants will self-administer JNJ-54861911 tablet, 5 mg, orally, once daily.
Study NCT00775801 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FLD
Description: Artificial lumbar disc
Study NCT00775801 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Artificial lumbar disc
Study NCT00789373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Induction therapy: 500 mg/m\^2, intravenous (IV), on Day 1 of each 21-day cycle for 4 cycles
Study NCT00789373 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pemetrexed
Description: Induction therapy: 500 mg/m\^2, intravenous (IV), on Day 1 of each 21-day cycle for 4 cycles
Study NCT00789373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Induction therapy: Cisplatin: 75 mg/m\^2, IV, on Day 1 of each 21-day cycle for 4 cycles
Study NCT00789373 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: Induction therapy: Cisplatin: 75 mg/m\^2, IV, on Day 1 of each 21-day cycle for 4 cycles
Study NCT00789373 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maintenance therapy: Normal saline (0.9% sodium chloride) administered IV on Day 1 every 21-day cycle until progressive disease or treatment discontinuation
Study NCT00789373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Maintenance therapy: 500 mg/m\^2, IV, on Day 1 of each 21-day cycle until progressive disease or treatment discontinuation.
Study NCT00789373 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Supportive Care
Description: Best Supportive Care is treatment given with the intent to maximize quality of life. Best Supportive Care excludes any treatment in which the goal is to cure or slow the progression of the study disease. Patients will receive Best Supportive Care as judged by their treating physician. Those therapies considered acceptable include, but are not limited to, palliative radiation to extrathoracic structures, antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, and/or nutritional support (enteral or parenteral).
Study NCT00789373 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Best Supportive Care
Description: Best Supportive Care is treatment given with the intent to maximize quality of life. Best Supportive Care excludes any treatment in which the goal is to cure or slow the progression of the study disease. Patients will receive Best Supportive Care as judged by their treating physician. Those therapies considered acceptable include, but are not limited to, palliative radiation to extrathoracic structures, antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, and/or nutritional support (enteral or parenteral).
Study NCT02085629 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Donor M reg (Mreg_UKR)
Description: Experimental: M reg treatment~Donor M reg (2.5-7.5 million cells/kg) IV infused (6-7d before Tx) into recipients of a living donor renal Tx. Recipients also receive prednisolone, mycophenolate mofetil and tacrolimus background immunosuppression (as described in detail in the arm description).
Study NCT03412734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Description: Chlorhexidine preparation solutions
Study NCT03412734 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iodine
Description: Iodine-based preparation solutions
Study NCT01534039 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sur-Fit Natura
Description: ConvaTec Moldable Skin Barrier for ostomy patients
Study NCT01534039 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FormaFlex
Description: Hollister skin barrier for ostomy patients
Study NCT00927862 — intervention group
Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: IWPC adapted genotype-guided dosing algorithm for warfarin
Description: Within the first or second dose, apply an International Warfarin Pharmacogenetics Consortium (IWPC) adapted genotype-guided dosing algorithm to determine the daily maintenance dose of warfarin, based on clinical factors (age, sex, weight, height, etc.), and VKORC1 and CYP2C9 genotypes, to individualize the initial dosing of warfarin. (IWPC algorithm submitted for publication, 5-08)~Note that a second comparison will be made between the combined genotype-guided dosing groups (standard and modified IWPC warfarin dosing algorithms) and a historical comparator group.
Study NCT00927862 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Modified IWPC genetic-guided warfarin dosing algorithm
Description: Within the first or second warfarin dose, apply a modified International Warfarin Pharmacogenetics Consortium (IWPC)-adapted genotype-guided dosing algorithm to determine the daily maintenance dose of warfarin. The active comparator algorithm (see above) will be further modified to account for the temporal pharmacodynamics of warfarin metabolism, e.g., by ignoring the CYP2C9 variants for the first 2 days.~Note that a second comparison will be made between the combined genotype-guided dosing groups (standard and modified IWPC warfarin dosing algorithms) and a historical comparator group.
Study NCT00927862 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of care treatment
Description: The parallel, standard-dosing patient control cohort was identified by a query of the electronic medical records databases of the 3 participating hospitals for the time interval spanning enrollment of the randomized pharmacogenetic cohorts (July 2008-December 2010). Patients >=18 years of age initiating warfarin therapy with a baseline and at least 1 follow-up INR level between days 3 and 14 were selected. Initial dose selection and therapy modification was at individual Intermountain-credentialed physician/healthcare provider discretion. Standard management is non-PG-based. A standard (fixed) initial maintenance dose of 5 mg/d is generally assumed.
Study NCT04042623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVB-S6-500
Description: AVB-S6-500 is experimental drug
Study NCT04152811 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cooking Matters for Diabetes
Description: Each Cooking Matters course is made up of 6, 2-hour, weekly classes with 15 participants. The curricula is based on the Dietary Guidelines for Americans, MyPlate, the American Diabetes Association Standards of Medical Care in Diabetes 2017 and Medical Nutrition Therapy Evidence Based Guide for Practice/Nutrition Protocol as the foundation for basic nutrition guidelines, then builds upon these ideas using the collective groups' needs and interest to provide interactive lessons to teach cooking, food safety and food resource management with emphasis placed on blood sugar management.
Study NCT04152811 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Diabetes Care
Description: Usual Diabetes Care